Baricitinib: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ===COVID=== ==Pediatric Dosing== ==Special Populations== =...") |
No edit summary |
||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | ===[[COVID]]=== | ||
*Duration of therapy is up to 14 days or until hospital discharge | |||
*Dose dependent on eGFR | |||
**eGFR ≥60 mL/min/1.73 m2: 4 mg PO once daily | |||
**eGFR 30 to <60 mL/min/1.73 m2: 2 mg PO once daily | |||
**eGFR 15 to <30 mL/min/1.73 m2: 1 mg PO once daily | |||
**eGFR <15 mL/min/1.73 m2: Not recommended. | |||
Latest revision as of 21:02, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
- Duration of therapy is up to 14 days or until hospital discharge
- Dose dependent on eGFR
- eGFR ≥60 mL/min/1.73 m2: 4 mg PO once daily
- eGFR 30 to <60 mL/min/1.73 m2: 2 mg PO once daily
- eGFR 15 to <30 mL/min/1.73 m2: 1 mg PO once daily
- eGFR <15 mL/min/1.73 m2: Not recommended.
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion: